NCT00077454: Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors |
|
|
| Completed | 1 | 95 | US | erlotinib hydrochloride, CP-358,774, erlotinib, OSI-774, temozolomide, SCH 52365, Temodal, Temodar, TMZ, pharmacological study, pharmacological studies, laboratory biomarker analysis | National Cancer Institute (NCI) | Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Brain Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma | 09/07 | | | |
